Announced
Completed
Financials
Tags
Cross Border
treatment development
Biotechnology
Acquisition
Majority
Public
United States
biopharmaceuticals
rare diseases
Friendly
cancer treatment
Single Bidder
Tender Offer
Completed
Synopsis
Merck, a German multinational pharmaceutical, chemical and life sciences company, completed the acquisition of ArQule, a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases, for $2.7bn. "ArQule’s focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties. This acquisition strengthens Merck’s pipeline with the addition of these strategic assets including, most notably, ARQ 531, a compelling candidate for the treatment of B-cell malignancies," Roger M. Perlmutter, Merck Research Laboratories President.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.